Healthcare Sector
Market Tracker
15m Chart - Support and Resistance levels are based on the large dark pool & equity prints at the plotted levels. Displays strongest levels above and below the spot price.
Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.
Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.
Represents the largest cumulative premium levels above and below the current spot price. The price in the pink bubble represents the spot price.
Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.
| Expires | Type | Strike | OI | Change | Percent |
|---|---|---|---|---|---|
| 07/18/2025 | CALL | $105.00 | 9,057 | +2,322 | +34.48% |
| 01/16/2026 | CALL | $110.00 | 1,120 | +169 | +17.77% |
| 01/15/2027 | CALL | $115.00 | 121 | +94 | +348.15% |
| 07/18/2025 | PUT | $105.00 | 516 | +65 | +14.41% |
| 07/18/2025 | PUT | $100.00 | 1,417 | +57 | +4.19% |
| 08/15/2025 | PUT | $100.00 | 245 | +44 | +21.89% |
| 07/18/2025 | CALL | $75.00 | 393 | -25 | -5.98% |
| 09/19/2025 | PUT | $100.00 | 178 | -29 | -14.01% |
| 07/18/2025 | CALL | $95.00 | 149 | -30 | -16.76% |
| 09/19/2025 | CALL | $80.00 | 426 | -37 | -7.99% |
| 09/19/2025 | CALL | $90.00 | 247 | -39 | -13.64% |
| 07/18/2025 | CALL | $85.00 | 87 | -75 | -46.30% |
Contracts with largest changes in open interest from the previous trading day to the current/most recent.
| Name | Pct Held | Shares | Total |
|---|---|---|---|
| PGIM Jennison Health Sciences Fd | 1.35% | 699.24k | 14.68M |
| Fidelity Select Portfolios - Biotechnology | 1.04% | 538k | 11.29M |
| Fidelity Advisor Biotechnology Fund | 0.93% | 484.37k | 10.17M |
| Fidelity Select Portfolios - Health Care | 0.77% | 400k | 8.4M |
| Fidelity Contrafund Inc | 0.70% | 363.05k | 7.62M |
| iShares NASDAQ Biotechnology ETF | 0.58% | 302.98k | 6.36M |
| Fidelity Advisor Health Care Fund | 0.54% | 280k | 5.88M |
| Hartford Healthcare Fund | 0.48% | 246.65k | 5.18M |
| Fidelity Series Small Cap Opportunities Fund | 0.40% | 208.51k | 4.38M |
| Vanguard Whitehall Funds-International Explorer Fund | 0.34% | 175.13k | 3.68M |
Nvidia's $4 Trillion Milestone Lifts Wall Street: What's Moving Markets Wednesday?
07/09 02:19 pm
Benzinga
Read moreMerck Strikes $10-Billion Deal For Verona, Secures First-In-Class COPD Drug
07/09 09:03 am
Benzinga
Read moreInvesting $15,000 Into Each of These 3 Stocks 5 Years Ago Would Have Created a Portfolio Worth $1 Million Today
06/05 11:22 am
The Motley Fool
Read moreRegeneron, Sanofi Stock Falls After Uneven Smoker's Lung Drug Data
05/30 08:30 am
Benzinga
Read moreVerona Pharma Announces June 2025 Investor Conference Participation
05/21 06:00 am
GlobeNewswire Inc.
Read moreVerona Pharma to Present Seven Analyses of the Phase 3 ENHANCE Studies in COPD at ATS 2025
05/06 06:00 am
GlobeNewswire Inc.
Read moreVerona Pharma Reports First Quarter 2025 Financial Results and Provides Corporate Update
04/29 06:00 am
GlobeNewswire Inc.
Read moreVerona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update
04/15 06:00 am
GlobeNewswire Inc.
Read moreVerona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update
02/13 07:00 am
GlobeNewswire Inc.
Read moreBronchiectasis Market to Show Positive Growth at a CAGR of 13.7% by 2034 | DelveInsight
01/21 02:00 pm
GlobeNewswire Inc.
Read moreVerona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights
01/07 07:00 am
GlobeNewswire Inc.
Read moreVerona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/04 03:00 am
GlobeNewswire Inc.
Read moreVerona Pharma to Present at 44th Annual Canaccord Growth Conference
07/30 02:00 am
GlobeNewswire Inc.
Read moreLGND reaches 52-week high, hitting $103.295 - Investing.com
07/23 03:16 pm
Investing.com
Read moreFDA Delays Decision on Sanofi (SNY)-Regeneron Dupixent in COPD
05/31 09:35 am
Zacks Investment Research
Read more3 Healthcare Stocks That Have Outperformed Nvidia Since 2022
03/01 09:45 am
The Motley Fool
Read moreLigand (LGND) Q4 Earnings Surpass Estimates, Stock Surges
02/28 08:34 am
Zacks Investment Research
Read more3 Stocks That Could Be Monster Winners in 2024
12/30 07:50 am
The Motley Fool
Read moreVerona Pharma's Promising COPD Treatment Puts It in GSK's Acquisition Crosshairs, Analysts Predict Big Moves
12/29 02:24 pm
Benzinga
Read moreFluor Corporation and Align Technology have been highlighted as Zacks Bull and Bear of the Day
12/26 09:45 am
Zacks Investment Research
Read more3 Beaten-Down Biotech Stocks to Buy for a Turnaround in 2024
12/22 10:46 am
Zacks Investment Research
Read moreLigand (LGND) Posts Long-Term Outlook, Updates Portfolio Progress
12/13 12:57 pm
Zacks Investment Research
Read moreVerona Pharma's Ensifentrine: Potentially A New Era In Respiratory Disease Treatment
11/18 03:54 am
Seeking Alpha
Read moreLigand (LGND) Beats on Q3 Earnings & Sales, Raises '23 View
11/09 02:27 pm
Zacks Investment Research
Read moreExpert Ratings for Verona Pharma
09/01 11:00 am
Benzinga
Read moreVerona Pharma: Ensifentrine Vs. Dupixent, Ensifentrine Is A Breath Of Fresh Air
04/16 01:22 am
Seeking Alpha
Read moreCharles Schwab To Rally Over 19%? Here Are 10 Other Analyst Forecasts For Monday
03/20 12:37 pm
Benzinga
Read more4 Analysts Have This to Say About Verona Pharma
03/13 01:01 pm
Benzinga
Read moreVerona Pharma: Strong Stock Growth Potential From A Promising New Drug
03/12 04:00 am
Seeking Alpha
Read moreVerona (VRNA) to Report Q4 Earnings: What's in the Cards?
02/15 12:49 pm
Zacks Investment Research
Read moreTop 10 Stocks For 2023
01/05 03:00 am
Seeking Alpha
Read morePDS Biotechnology, Pulmonx, Tesla And Some Other Big Stocks Moving Lower On Tuesday
01/03 12:01 pm
Benzinga
Read moreThe Zacks Analyst Blog Highlights AVEO Pharmaceuticals, Cabaletta Bio, Verona Pharma and Wave Life Sciences
01/03 06:40 am
Zacks Investment Research
Read more